Nme inhibitors and methods of using nme inhibitors
AssigneeMinerva Biotechnologies Corporation
InventorsCynthia BAMDAD, Benoit Smagghe
Life of this patent
Estimating the term…
Abstract
The present application discloses inhibitors of NME family of proteins.
Claims72
An agent that inhibits function of an NME family member protein.
A method for treating a patient with cancer or at risk of developing cancer comprising administering to the patient an effective amount of an agent that inhibits tumorigenic activity of an NME family member protein.
A method for treating a patient with cancer or at risk of developing cancer comprising administering to the patient an effective amount of NME1 as a hexamer.
A method for treating a patient with cancer or at risk of developing cancer comprising administering to the patient an effective amount of NME6 as a monomer.
A method for treating a patient with cancer or at risk of developing cancer comprising administering to the patient an effective amount of NME1 as a monomer.
A method for treating a patient with cancer or at risk of developing cancer comprising administering to the patient an effective amount of a peptide or peptide mimic that inhibits the interaction of the NME family member with its cognate receptor.
A method for classifying cancers or stratifying patients, having or suspected of having cancer, comprising the steps of:
- (i) analyzing a patient sample for the presence of stem or progenitor cell genes or gene products;
- and
- (ii) grouping patients who share similar expression or expression levels of stem or progenitor cell genes or gene products.
An agent that inhibits the interaction of an NME family member protein and a MUC1 transmembrane protein whose extracellular domain is devoid of the tandem repeat domain, wherein the agent binds to MUC1* on cancer cells with a higher affinity than its binding to the MUC1 transmembrane protein whose extracellular domain is devoid of the tandem repeat domain present on healthy cells in an adult.
A method of inhibiting interaction of an NME family member protein and a MUC1 transmembrane protein whose extracellular domain is devoid of the tandem repeat domain in a cell, comprising contacting the cell with an agent that binds to MUC1* on cancer cells with a higher affinity than its binding to the MUC1 transmembrane protein whose extracellular domain is devoid of the tandem repeat domain on healthy cells in an adult.
A transgenic mammal that expresses human NME protein in the germ cells and somatic cells, wherein the germ cells and somatic cells contain a nucleic acid encoding human NME introduced into said mammal.
A method of generating a mammal that responds to cancer in a way that more closely resembles the response of a human wherein the mammal is a mammal in which human NME protein is expressed.
A method for increasing engraftment of human tumors in mammals, comprising mixing the human tumor cells with NME1 dimers or NME7 monomers prior to injecting the cells into the test mammals.
A method for generating an antibody comprising injecting an NME family protein or peptide fragment or fragments thereof into a mammal and harvesting the antibody or antibody producing cell.
A method of generating or selecting an antibody or antibody-like molecule that specifically binds to NME family protein or peptide fragment thereof, comprising:
- (i) screening an antibody library or library of antibody fragments or epitopes with the NME family protein or peptide fragment;
- (ii) assaying for binding to the NME family protein or a peptide fragment thereof;
- and
- (iii) identifying the specifically bound antibody or antibody-like molecule.
A method of preventing cancer by vaccinating a person with an NME family protein or peptide fragment or fragments thereof.
Dependencies are inferred from the claim text.